Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Q&A: Hanna Persson, Head of Sales, Ress Capital

    Secondary Life Markets April 13, 2023By Greg Winterton
    Life Risk News Q&A
    Share
    Twitter LinkedIn Email

    Stockholm-based asset manager Ress Capital is a specialist investor in life settlements and runs one of the few listed vehicles active in the space. Greg Winterton spoke to Hanna Persson, Head of Sales at Ress Capital, to learn more about the firm itself and its approach to the space.

    GW: Hanna, Ress Capital’s investment vehicle is publicly listed, on the Nasdaq Nordic exchange. Why did the firm decide to go that route?

    HP: The open-ended structure enables gradual growth, and policies can be gradually sourced. It also allows the fund to buy longer life expectancies which a closed-end fund could not do with a buy and hold strategy. We wanted to make this very interesting asset class more accessible to investors that would not necessarily be able to invest in the life settlement market otherwise. Being listed allows different type of investors from all over the world to buy shares easily through their local bank/broker.

    GW: Tell us about your approach to policy selection. What are some of the features that you look for in policies that make it into your portfolio, and why?

    HP: In the end, using correct mortality assumptions will of course be most important and we tend to be on the conservative side there. But for policy selection, our investment team focuses on limiting the tail risk of the portfolio both at an individual policy as well as portfolio level. This is achieved by reviewing large numbers of policies and then buying single, high-quality policies. We are very selective and buy only 3-4% of the policies we look at.

    Hannah Persson
    Hanna Persson

    In general, we look for wealthier and relatively healthy individuals with long life expectancies (average life expectancy at purchase is 12 years) which we believe are more accurate. Then, by looking for stable future premium streams, the negative effect of any individual substantially outliving their life expectancy is reduced.

    At a portfolio level, we then always strive to have high level of diversification in terms of age, gender, size and life expectancy which should reduce the systemic risk of medical underwriters estimating longevity for sub-groups.

    GW: Ress Capital is a signatory to the United Nations’ Principles for Responsible Investments. Why did you decide to pursue this credential and what’s been the main benefit so far?

    HP: Being a responsible investor is an integral part of how we operate. Our clients should feel confident that we prioritise sustainability in our daily activities and that we always strive to improve our sustainability efforts. Being an alternative investment manager active in the secondary market for US life insurance policies, ethics is a key aspect.

    At Ress Capital, we are convinced that the future challenges we face will place new demands on us as managers of our clients’ capital. Through our work with responsible investments, we want to contribute to a more long-term and sustainable investment climate where environmental, social, and corporate governance (ESG) factors are included in the investment process. Responsible investments thus become an important prerequisite for achieving our goal of generating good long-term returns.

    As an essential part of Ress Capital’s commitment to sustainability and responsible investments, we signed the United Nations’ Principles of Responsible Investment (UNPRI) in 2017 meaning we supports the work carried out by UNPRI to promote sustainability work in the asset management industry.

    GW: There is disagreement amongst life settlement-focused investment managers about whether the asset class should be considered more akin to private equity or alternative credit. What’s Ress Capital’s view and why?

    HP: I wouldn’t say Ress Capital has taken any official stance on this. However, we believe the asset class potentially has similarities with alternative credit, although we would argue that the credit rating of US life insurance companies is far better and they’re also highly regulated. As regards similarities with private equity, since our fund is listed, it has little in common with closed-end PE funds with no liquidity. Also, we would argue that expected return profile is quite different from PE. 

    GW: Lastly, Hanna, what’s your message to institutional, end investors that don’t have an allocation to life settlements in their portfolio – what are the main reasons for doing so in your view?

    HP: This is an asset class that is fundamentally uncorrelated to majority of other asset classes. The underlying risk is decoupled from the economic cycle. When done correctly, life settlements as an asset class offers a fixed income alternative with yields comparable to those of an equity portfolio, but with volatility below that of investment grade bonds. In times of high volatility in the market life settlements present a unique, stable and truly uncorrelated return stream.

    Hanna Persson is Head of Sales at Ress Capital

    2023 - April Life Settlements Longevity Risk Q&A Volume 2 Issue 4 - April 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026By Greg Winterton

    Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

    November 11, 2026By LMI Newsdesk

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026By Greg Winterton

    Q&A: Alexandr Dudarev, CEO, Inshurik

    October 28, 2026By Greg Winterton
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.